Recommendation to Continue Administration of Respiratory Syncytial Virus (RSV) Monoclonal Antibody Products Beyond March 31, 2026
Description
This memo provides notification of an extension for the use of RSV monoclonal antibody products for infants and young children.
Memo Issued By
DPH
Official Memo Number
BCD 2026-03
Memo Issue Date
March 17, 2026
Memo File